COVID-19 vaccines: Article 5(3) reviews
The European Medicines Agency (EMA) may review COVID-19 vaccines under Article 5(3) of the Regulation establishing EMA (Regulation (EC) No 726/2004).
This is intended to support national decision-making on the use of these vaccines.
|Vaccine||Key milestones||More information|
|Vaxzevria (previously COVID-19 Vaccine AstraZeneca)|
Start of review: 14/04/2021
Interim opinion: 23/04/2021
|Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021|
AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets
AstraZeneca’s COVID-19 vaccine: benefits and risks in context
Article 5(3) opinions: Use of Vaxzevria to prevent COVID-19
For more information, see: